Core Viewpoint - China Resources Pharmaceutical (03320) has successfully issued the first phase of its 2025 medium-term notes, raising a total of RMB 3 billion with a maturity of three years and an annual interest rate of 2.19 [1] Group 1 - The first phase of the 2025 medium-term notes was completed on December 15, 2025 [1] - The funds raised from this issuance will be used to repay interest-bearing debts of China Resources Pharmaceutical Commercial or its subsidiaries [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) has successfully issued the first phase of its 2025 medium-term notes, raising a total of RMB 3 billion with a maturity of three years and an annual interest rate of 2.19 [1] Group 1 - The first phase of the 2025 medium-term notes has been issued by China Resources Pharmaceutical's non-wholly owned subsidiary, China Resources Pharmaceutical Commercial Group [1] - The total amount raised from the issuance is RMB 3 billion [1] - The funds raised will be used to repay interest-bearing debts of China Resources Pharmaceutical Commercial or its subsidiaries [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 1 本公司股東及有意投資者於買賣本公司證券時務請審慎行事。 承董事會命 華潤醫藥集團有限公司 主席 （於香港註冊成立的有限公司） （股份代號：3320） 內幕消息 於中國完成發行第一期2025年中期票據 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條 及香港法例第571章證券及期貨條例第XIVA部之內幕消息條文（定義見上市規 則）之規定而發出。 茲提述華潤醫藥集團有限公司（「本公司」）日期為2025年12月1日的公告（「該公 告」），內容有關（其中包括）於中國擬議發行中期票據。除本公告另有訂明外， 本公告所用詞彙與該公告所界定者具有相同涵義。 董事會欣然宣佈，於2025年12月15日，本公司的非全資附屬公司華潤醫藥商 業集團有限公司（「華潤醫藥商業」）已於中國完成發行第一期2025年中期票據 （「 2025年中期票據」）。本金額人民幣30億元的第一期2025年中期票據已發 ...

Group 1 - The core point of the article is the announcement of a change in the company secretary and authorized representative at China Resources Pharmaceutical Group Limited (华润医药) [1] - Zheng Guiyu has resigned from the position of company secretary and authorized representative, effective December 15, 2025 [1] - Wen Yongyi has been appointed as the new company secretary and authorized representative, also effective December 15, 2025 [1] Group 2 - China Resources Pharmaceutical Group Limited has received approval from the National Association of Financial Market Institutional Investors for the issuance of 3 billion yuan medium-term notes [1]

Group 1 - The company announced that Ms. Zheng Guiyu will resign as the company secretary effective December 15, 2025, and will no longer serve as the authorized representative under the Hong Kong Stock Exchange Listing Rules [1] - The board is pleased to announce that Ms. Wen Yongyi has been appointed as the company secretary and authorized representative, effective December 15, 2025 [1] - Ms. Wen has over 11 years of experience in the company secretarial industry and is a member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the UK [1] Group 2 - Ms. Wen holds a Bachelor of Science degree in Business from the University of London and a Master's degree in Corporate Governance from the Open University of Hong Kong (now known as the Hong Kong Metropolitan University) [1]

Group 1 - The core announcement is that Ms. Zheng Guiyu has resigned as the company secretary of China Resources Pharmaceutical (03320) effective December 15, 2025, and will no longer serve as the authorized representative under the Hong Kong Stock Exchange Listing Rules [1] - The board has appointed Ms. Wen Yongyi as the new company secretary and authorized representative, effective from December 15, 2025 [1] - Ms. Wen has over 11 years of experience in the company secretarial industry and is a member of both the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the UK [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 董事會欣然宣佈温詠宜女士（「温女士」）獲委任為公司秘書及授權代表，自二零二五年十 二月十五日起生效。温女士現為方圓企業服務集團（香港）有限公司的經理，在公司秘書行 業擁有逾十一年經驗。温女士為香港公司治理公會及英國特許公司治理公會的會員。温女士 畢業於英國倫敦大學並獲授予商學理學士學位，彼亦持有香港公開大學（現稱香港都會大 學）企業管治碩士學位。 董事會藉此機會向鄭女士於任期內對本公司作出的寶貴貢獻表示謝意，亦謹此歡迎温女士履 新。 承董事會命 華潤醫藥集團有限公司 主席 白曉松先生 中國，二零二五年十二月十五日 於本公告日期，董事會包括本公司主席及執行董事白曉松先生；本公司執行董事程杰先生及 劉長安先生；本公司非執行董事郭巍女士、孫永強先生、王宇航先生、郭川先生及焦瑞芳女 士；及本公司獨立非執行董事招敏慧女士、傅廷美先生、張克堅先生及史錄文先生。 （於香港註冊成立的有限公司） （股份代號：3320） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 持續關連交易 2025年框架貸款協議 茲提述日期為2023年4月3日的公告，內容有關2023年框架貸款協議。由於 2023年框架貸款協議及其項下年度上限將於2025年12月31日到期及失效，於 2025年12月15日，本公司分別與華潤股份及華潤（集團）訂立2025年框架貸款 協議，各協議自2026年1月1日起至2028年12月31日止為期三年。 於本公告日期，本公司的控股股東華潤（集團）間接持有本公司約53.40%權 益，而華潤股份為華潤（集團）的控股股東。因此，華潤股份及華潤（集團）各 自為本公司的關連人士，根據上市規則第14A章，2025年框架貸款協議項下 擬進行的交易構成本公司的持續關連交易。 由於一項或多項有關2025年框架貸款協議項下持續關連交易的年度上限的 適用規模測試比率高於0.1%但低於5%，故該等交易僅須遵守上市規則項下 的申報、 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 持續關連交易 經修訂2026年商務旅遊服務框架協議 茲提述本公司與華潤數科簽訂關於經修訂2025年商務旅遊服務框架協議之該公 告。 茲 提 述 本 公 司 與 華 潤 數 科 簽 訂 關 於 經 修 訂 2025 年 商 務 旅 遊 服 務 框 架 協 議 之 該 公 告。 於 2025 年 12 月 10 日 ， 本 公 司 與 華 潤 數 科 訂 立 經 修 訂 2026 年 商 務 旅 遊 服 務 框 架 協 議，期限自經修訂2026年商務旅遊服務框架協議日期起至2027年12月31日止，以 反映經修訂2025年商務旅遊服務框架協議項下擬進行的交易的經修訂建議年度上 限。經修訂2025年商務旅遊服務框架協議已被經修訂2026年商務旅遊服務框架協 議取代並於2025年12月10日停 ...

Core Insights - The pharmaceutical distribution industry is a crucial component of the national healthcare system and health industry, significantly impacting public health and safety [1][7] - The industry is experiencing growth due to the implementation of the "two-invoice system" reform and increasing public awareness of healthcare [1][7] Industry Overview - The pharmaceutical distribution market in China is projected to reach a sales volume of 29,470 billion yuan in 2024, with wholesale sales accounting for 22,970 billion yuan (77.94%) and retail sales for 6,500 billion yuan (22.06%) [1][7] - The regional distribution of sales shows that East China accounts for 36.3%, Central South 27.0%, North China 15.2%, Southwest 13.4%, Northeast 4.3%, and Northwest 3.8%, with the top three regions contributing to 78.5% of total sales [9][10] Sales Structure - The sales composition indicates that Western medicine accounts for 70.8% of total sales, followed by traditional Chinese medicine at 14.6%, medical devices at 7.7%, and other categories [9][10] Current State of the Industry - As of the end of 2024, there are 705,400 licensed pharmaceutical businesses in China, including 15,100 wholesale companies and 66,070 retail chain enterprises [3][5] - The total number of retail pharmacies has increased to 683,700, with a notable rise in single retail pharmacies [3][5] Financial Performance - In 2024, the main business income of reported pharmaceutical distribution enterprises reached 22,431 billion yuan, reflecting a 0.8% increase from 2023, while the profit totaled 468 billion yuan with an average gross margin of 7.2% [5][6] Industry Chain - The pharmaceutical distribution industry serves as a critical link in the pharmaceutical supply chain, connecting manufacturers with end-users, including hospitals and pharmacies [11][12] Competitive Landscape - Major players in the pharmaceutical distribution sector include East China Pharmaceutical, Shanghai Pharmaceutical, China National Pharmaceutical Group, and others, with significant revenue contributions from these companies [14][15] Future Development Directions - The industry aims to enhance operational efficiency and inventory management to ensure a stable supply of pharmaceuticals while minimizing financial risks [18][19]